InvestorsHub Logo
Followers 66
Posts 12724
Boards Moderated 0
Alias Born 06/03/2015

Re: Gambit53 post# 413445

Tuesday, 05/02/2023 10:22:50 AM

Tuesday, May 02, 2023 10:22:50 AM

Post# of 462250
Let's review, again, the results of the "P3" AD trial...

1. All endpoints met: ADAS-Cog, ADCS-ADL and CDR-SB.

2. Highlight of Super Responders, for both cognition and functionality, emphasized by Odds Ratios.

KEM and subgroup analysis, MRI results and Sleep Study data are forthcoming to detail the efficacy aspects and demonstrate additional benefits in the study.

It's that simple.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News